Literature DB >> 11139370

Increased nitric oxide production in patients with systemic sclerosis.

A Sud1, M Khullar, A Wanchu, P Bambery.   

Abstract

Nitric oxide (NO, nitrogen monoxide) is a messenger molecule whose synthesis can be induced by proinflammatory cytokines. Increased production of NO has been reported in various inflammatory and autoimmune diseases. We studied serum nitrite and citrulline as surrogate markers for NO production in patients with systemic sclerosis (SSc) and looked for correlation with extent of disease, disease duration, age, and systemic involvement. Thirty-four patients were studied against 20 controls. The nitrite levels were significantly higher in the disease group (1588.4 +/- 998.2 nmol/ml compared to 327.8 +/- 137.7 nmol/ml; P < 0.001). The citrulline levels of the disease group were also significantly higher (5490.1 +/- 2518.3 nmol/ml compared to 3264.5 +/- 2509.7 nmol/ml in the controls; P = 0.005). There was no significant difference among limited and diffuse subgroups. There was no significant difference in patients with or without arthritis or interstitial lung disease or with other systemic involvement. On multivariate analysis there was a trend toward a rising level of nitrite with worsening lung functions (P = 0.07). Hence, there is evidence of increased NO production in patients with SSc. There is no difference between NO levels in disease subgroups or those with systemic involvement. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11139370     DOI: 10.1006/niox.2000.0309

Source DB:  PubMed          Journal:  Nitric Oxide        ISSN: 1089-8603            Impact factor:   4.427


  11 in total

1.  Nitrite, a reactive nitrogen species, protects human alpha-2-macroglobulin from halogenated oxidant, HOCl.

Authors:  M Wasim Khan; Ashreeb Naqshbandi; Haseeb Zubair; Haseeb Ahsan; Shakil A Khan; Fahim H Khan
Journal:  Protein J       Date:  2010-05       Impact factor: 2.371

Review 2.  A Narrative Review of Pathogenetic and Histopathologic Aspects, Epidemiology, Classification Systems, and Disease Outcome Measures in Systemic Sclerosis.

Authors:  Maria-Grazia Lazzaroni; Silvia Piantoni; Fabrizio Angeli; Stefania Bertocchi; Franco Franceschini; Paolo Airò
Journal:  Clin Rev Allergy Immunol       Date:  2022-03-07       Impact factor: 10.817

3.  Comparison of serum nitric oxide levels in active juvenile rheumatoid arthritis with those of patients in remission.

Authors:  Alpana Beri; Surjit Singh; Anju Gupta; Madhu Khullar
Journal:  Rheumatol Int       Date:  2003-10-31       Impact factor: 2.631

4.  Inhibition of hypochlorous acid-induced cellular toxicity by nitrite.

Authors:  Matthew Whiteman; D Craig Hooper; Gwen S Scott; Hilary Koprowski; Barry Halliwell
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-09       Impact factor: 11.205

5.  Serum nitric oxide (NO) levels in systemic sclerosis patients: correlation between NO levels and clinical features.

Authors:  K Takagi; Y Kawaguchi; M Hara; T Sugiura; M Harigai; N Kamatani
Journal:  Clin Exp Immunol       Date:  2003-12       Impact factor: 4.330

6.  Serum nitric oxide metabolites and disease activity in patients with systemic sclerosis.

Authors:  Mo Yin Mok; Peter Chin Wah Fung; Clara Ooi; Hung Fat Tse; Yik Wong; Yui Ming Lam; Woon Sing Wong; Chak Sing Lau
Journal:  Clin Rheumatol       Date:  2007-08-15       Impact factor: 2.980

7.  Modulation of fibrosis in systemic sclerosis by nitric oxide and antioxidants.

Authors:  Audrey Dooley; K Richard Bruckdorfer; David J Abraham
Journal:  Cardiol Res Pract       Date:  2011-10-31       Impact factor: 1.866

8.  NOS2 polymorphisms associated with the susceptibility to pulmonary arterial hypertension with systemic sclerosis: contribution to the transcriptional activity.

Authors:  Yasushi Kawaguchi; Akiko Tochimoto; Masako Hara; Manabu Kawamoto; Tomoko Sugiura; Yasuhiro Katsumata; Jun Okada; Hirobumi Kondo; Mitsuo Okubo; Naoyuki Kamatani
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

9.  Oxidative damage and antioxidative therapy in systemic sclerosis.

Authors:  Bogna Grygiel-Górniak; Mariusz Puszczewicz
Journal:  Mediators Inflamm       Date:  2014-09-08       Impact factor: 4.711

10.  Reduced levels of S-nitrosothiols in plasma of patients with systemic sclerosis and Raynaud's phenomenon.

Authors:  Devi Kundu; David Abraham; Carol M Black; Christopher P Denton; K Richard Bruckdorfer
Journal:  Vascul Pharmacol       Date:  2014-10-15       Impact factor: 5.773

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.